Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (124)

« Back to Publications

Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.

Kimathi D. et al, (2026), Lancet (London, England)

Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.

Waweru G. et al, (2025), Viruses, 17

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)

Belij-Rammerstorfer S. et al, (2025), eBioMedicine, 118, 105847 - 105847

Rift Valley fever seroprevalence and risk factors among human populations in Uganda’s cattle corridor: a cross-sectional study

Anywaine Z. et al, (2025), BMJ Public Health, 3, e002563 - e002563

Comparative performance of the InBios SCoV-2 DetectTM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations

Kutima B. et al, (2025), Wellcome Open Research, 9, 349 - 349

Low-Dose Yellow Fever Vaccine in Adults in Africa

Kimathi D. et al, (2025), New England Journal of Medicine, 392, 788 - 797

Stakeholder meeting report: Chikungunya virus - recent outbreaks, vaccine development and the way forward

Kang H. et al, (2025), VACCINE: X, 27

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study

Kimotho J. et al, (2024), Wellcome Open Research, 8, 350 - 350

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.

Lugano D. et al, (2024), BMC infectious diseases, 24

Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data

Ojal J. et al, (2024)

Comparative performance of the InBios SCoV-2 DetectTM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations

Kutima B. et al, (2024), Wellcome Open Research, 9, 349 - 349

Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines.

Juan-Giner A. and Warimwe G., (2024), The Lancet. Infectious diseases, 24, 562 - 564

Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda.

Anywaine Z. et al, (2024), Virology journal, 21

Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.

Kagucia EW. et al, (2024), Gates open research, 8

Comparative performance of the InBios SCoV-2 Detect TM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations.

Kutima B. et al, (2024), Wellcome open research, 9

Load More

1
2
3
4
5
6
7
...
»